1,721,479 research outputs found

    Naive CD4+ T cells from patients with atopic dermatitis show an aberrant maturation towards IL-4-producing skin-homing CLA+

    No full text
    Overproduction of interleukin-4 (IL-4) has been reported in lesional and in peripheral T cells from patients with atopic dermatitis ( AD). It is not clear whether the development of IL-4-producing T helper type 2 (Th2) cells from naive precursors is an intrinsic phenomenon of T cells or whether other, extrinsic factors play a significant role. To analyze these alternatives, we investigated the IL-4 production of effector T cells generated in vitro from highly purified CD4+ CD45RA+ naive T cells in the absence of signals derived from antigen-presenting cells. Effector T cells generated from naive precursors from both AD and healthy donors produced comparable amounts of IL-4 after restimulation. Priming in the presence of exogenous IL-4 enhanced the production of IL-4 while neutralizing endogenously produced IL-4 abolished IL-4 production similarly in atopic and healthy T cells. A subset of effector T cells acquired the expression of the cutaneous lymphocyte antigen (CLA). The frequency of CLA+ T cells was not different between atopic and healthy donors. CLA+ T cells, differentiated from naive atopic, but not healthy T cells, showed a preferential Th2 cytokine profile as assessed by intracellular cytokine staining. Also effector T cells derived from atopic patients without dermatitis tended to show this imbalance, although it was not significantly different to healthy controls. This Th2 cytokine profile did not develop when naive T cells were cultured in the presence of IL-12. In conclusion, high IL-4 production in developing T cells from AD patients was associated with CLA expression, the net IL-4 production of all effector CD4+ T cells, however, was similar to IL-4 production by T cells from healthy donors

    Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis

    No full text
    Because psoriatic arthritis (PsA) usually develops years after the first manifestation of skin symptoms, in many cases the initial diagnosis of PsA depends on the dermatologist. To investigate the prevalence and clinical pattern of PsA in a daily practice population of patients with psoriasis. Patients were enrolled in an observational prospective cross-sectional cohort study at 48 community and academic centres. Demographic and medical parameters were recorded, including severity of skin symptoms (Psoriasis Area and Severity Index, PASI), previous and current treatments, concomitant diseases, and the impact of psoriasis on productivity and health-related quality of life (Dermatology Life Quality Index, DLQI). Patients with joint symptoms were referred to a rheumatologist for diagnosis and to record the activity and pattern of arthritis. Among 1511 patients 20.6% had PsA; in 85% of the cases PsA was newly diagnosed. Of these patients more than 95% had active arthritis and 53.0% had five or more joints affected. Polyarthritis (58.7%) was the most common manifestation pattern, followed by oligoarthritis (31.6%) and arthritis mutilans (4.9%). Distal interphalangeal involvement was present in 41.0% and dactylitis in 23.7% of the patients. Compared with patients without arthritis, patients with PsA had more severe skin symptoms (mean PASI 14.3 vs. 11.5), a lower quality of life (mean DLQI 11.6 vs. 7.7) and greater impairment of productivity parameters. The findings are consistent with a high prevalence of undiagnosed cases of active PsA among patients with psoriasis seen by dermatologists. As many of these patients also have significant skin symptoms, treatment strategies are required that are equally effective in the control of skin and joint symptoms of psoriasis.Essex Pharma, German
    corecore